Viona Pharmaceuticals Inc. recalled Dapsone Gel 7.5% due to crystallization, the Food and Drug Administration said on Oct. 29, 2024. The voluntary Class II recall affects 6,048 pumps distributed nationwide.
How to tell if you have it
- Brand: Viona Pharmaceuticals
- Product: Dapsone Gel 7.5%, 60 gram pump
- NDC: 72578-094-02
- Lot codes: T401151 (Exp 06/30/2026), T400806 (Exp 03/31/2026)
- Manufacturer: Zydus Lifesciences Ltd., Ahmedabad, India
- Distributor: Viona Pharmaceuticals Inc., Cranford, NJ 07016
- Quantity: 6,048 pumps
The hazard
The recall addresses crystallization in the gel. The FDA classified the issue as a Class II recall.
Context
GovInfoNow's records show Viona Pharmaceuticals Inc. has six other recalls on record since June 1, 2021. Other recent recalls of similar products include Endo USA Buprenorphine Injection Recall: Crystallization Risk (March 13, 2026), Sun Pharmaceutical Diclofenac Gel Recall: Failed Viscosity Specifications (Jan. 27, 2026), and Par Health Buprenorphine Injection Recall: Crystallization Risk (June 12, 2026).